U.S. pharmaceutical company Zafgen which received technology from Chong Kun Dang reached NASDAQ listing value of about $ 400 million
U.S. pharmaceutical company Zafgen which received the technique of severe obesity treatment `CKD-732` (ingredient belolanip) from Chong Kun Dang recently listed in Nasdaq, and reached listing value of about $ 400 million (411 billion won). The technology of 'CKD-732` was exported to Zafgen in 200...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
